TY - JOUR
T1 - Antibody therapy for histoplasmosis
AU - Nosanchuk, Joshua D.
AU - Zancopé-Oliveira, Rosely M.
AU - Hamilton, Andrew J.
AU - Guimarães, Allan J.
PY - 2012
Y1 - 2012
N2 - The endemic human pathogenicfungusHistoplasmacapsulatum isamajor fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.
AB - The endemic human pathogenicfungusHistoplasmacapsulatum isamajor fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.
KW - Antibody
KW - Co-stimulation
KW - Heat shock protein 60
KW - Histone 2B
KW - Histoplasma capsulatum
KW - Histoplasmosis
KW - M antigen
UR - http://www.scopus.com/inward/record.url?scp=84864451340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864451340&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2012.00021
DO - 10.3389/fmicb.2012.00021
M3 - Article
C2 - 22347215
AN - SCOPUS:84864451340
SN - 1664-302X
VL - 3
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
IS - FEB
ER -
